Recce Pharmaceuticals (ASX:RCE) receives ‘intent to grant’ Patent Family 4 for anti-infectives

• Recce Pharmaceuticals (RCE) receives boost from the Australian Patent Office after announcing its ‘intent to grant’ the first of Recce’s new Patent Family 4 for anti-infectives
• The patent covers the “Process for Preparation of Biologically Active Copolymer”, with an expiry date set for 2041
• The Family 4 patent relates to Recce 327 (R327) and Recce 529 (R529) and covers the process for the preparation of Recce anti-infectives as well as the use of R327/R529 for the treatment of disease
• Recce confirmed Patent Cooperation Treaty Country (PCT) patent submissions are in respective stages of review
• RCE shares are up 1.74 per cent and trading at 58.5 cents at 1:16 pm AEST

Recce Pharmaceuticals (RCE) has received a boost from the Australian Patent Office after announcing its ‘intent to grant’ the first of Recce’s new Patent Family 4 for anti-infectives.

The patent covers the “Process for Preparation of Biologically Active Copolymer”, and will expire in 2041.

“With now over 40 patents around the world, validation of Recce’s new class of anti-infectives marketing/manufacturing monopolies to at least January 2041 are again welcomed as an addition to its intellectual property portfolio globally,” Recce CEO James Graham said.

Recce is developing a new class of synthetic anti-infectives, which are designed to address antibiotic-resistant superbugs and emerging viral pathogens.

The newest Family 4 patent relates to Recce 327 (R327) and Recce 529 (R529) and covers the process for the preparation of Recce anti-infectives as well as the use of R327 and R529 for the treatment of disease.

It further validates Recce’s anti-infectives from studies in burn wounds, urinary tract infections (UTIs), gonorrhoea, influenza, SARS-CoV-2 and more.

The patent covers both bacterial and viral pathogens.

It also relates to administration routes which include oral, topical, inhalation, transdermal delivery, or by injection into the bloodstream. Administration can also be applied as an aerosol, gel, topical foam or ointment.

RCE shares were up 1.74 per cent and trading at 58.5 cents at 1:16 pm AEST.